Jan 12, 2022 | Press Releases
Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing Practices (cGMP) facility with clean rooms will expedite capabilities for...
Jan 4, 2022 | Press Releases
NK cells engineered with a high-affinity CD16 receptor have the potential to enhance monoclonal antibody therapeutic effects against cancer cells Combination monoclonal antibody therapy and CD16 NK-92 cell therapy patent term to 2036 CULVER CITY, Calif., January 4,...
Jan 3, 2022 | Press Releases
EMERYVILLE and CULVER CITY, Calif., January 3, 2022 — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, and ImmunityBio (Nasdaq: IBRX), a...
Dec 20, 2021 | Press Releases
Year-End Review: SISONKE Universal Boost COVID T-Cell vaccine trial initiates Phase 3 enrollment in South Africa in previously vaccinated participants Increased GMP manufacturing capacity for RNA, DNA, Subunit Proteins, and Adjuvants vaccine platforms in U.S., South...
Nov 18, 2021 | Press Releases
Second-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and durable protection against current and future likely SARS-CoV-2 variants By adding self-amplifying self-adjuvating...
Nov 4, 2021 | Press Releases
CULVER CITY, Calif., November 4, 2021 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will deliver a...
